Ayala Pharmaceuticals Inc (fka ADXS)

[Funky_Omnivore]

GL,

I fully agree, LM IS better suited in the adjuvant setting than metastatic and also has much less competition in the market in this given setting. Given what we know about allogenic cancer vaccines coupled with heavy competition from PD-1's, I believe Dr. Petit made the conservative call on the AIM2CERV trial even if it does stretch out the trial duration. I have been invested in companies that have strung investors along, and I fully disagree with Roy that that is the intention of this trial. It is simply the trial where AXAL has the highest chances of scoring an FDA win and having a relatively broad application in the marketplace.